دورية أكاديمية
أعرض في EDS

Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection.

التفاصيل البيبلوغرافية
العنوان: Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection.
المؤلفون: Sciarra R; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Merli M; Division of Hematology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy., Cristinelli C; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Lucioni M; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Anatomic Pathology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Zibellini S; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Riboni R; Anatomic Pathology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Furlan D; Anatomic Pathology Unit, University of Insubria, Ospedale di Circolo, Varese, Italy., Uccella S; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; Pathology Service, IRCCS, Humanitas Research Hospital, Milan, Italy., Zerbi C; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Bianchi B; Division of Hematology, University Hospital Ospedale di Circolo e Fondazione Macchi-ASST Sette Laghi, Varese, Italy., Gotti M; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Ferretti VV; Biostatistics and Clinical Trial Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Varraso C; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Fraticelli S; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Anatomic Pathology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Lazic T; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Defrancesco I; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; Department of Medical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy., Mora B; Division of Hematology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy., Libera L; Anatomic Pathology Unit, University of Insubria, Ospedale di Circolo, Varese, Italy., Mazzacane A; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Carpi F; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Berliner M; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Neri G; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Rizzo E; enGenome s.r.l., Pavia, Italy., De Paoli F; enGenome s.r.l., Pavia, Italy., Sessa F; Anatomic Pathology Unit, University of Insubria, Ospedale di Circolo, Varese, Italy., Passamonti F; Division of Hematology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.; University of Milan, Milan, Italy., Paulli M; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Anatomic Pathology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Arcaini L; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
المصدر: British journal of haematology [Br J Haematol] 2024 Jun; Vol. 204 (6), pp. 2242-2253. Date of Electronic Publication: 2024 Mar 05.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford : Wiley-Blackwell
Original Publication: Oxford : Blackwell Scientific Publications
مواضيع طبية MeSH: Lymphoma, Large B-Cell, Diffuse*/genetics , Lymphoma, Large B-Cell, Diffuse*/virology , Hepatitis C*/complications , Hepatitis C*/genetics , Mutation*, Humans ; Male ; Aged ; Female ; Middle Aged ; Aged, 80 and over ; Hepacivirus/genetics ; Adult ; High-Throughput Nucleotide Sequencing
مستخلص: Hepatitis C virus (HCV)-associated diffuse large B-cell lymphoma (DLBCL) displays peculiar clinicopathological characteristics, but its molecular landscape is not fully elucidated. In this study, we investigated the clinicopathological and molecular features of 54 patients with HCV-associated DLBCL. The median age was 71 years. An underlying marginal zone lymphoma component was detected in 14.8% of cases. FISH analysis showed rearrangements involving BCL6 in 50.9% of cases, MYC in 11.3% and BCL2 in 3.7%. Lymph2Cx-based assay was successful in 38 cases, recognizing 16 cases (42.1%) as ABC and 16 cases as GCB subtypes, while six resulted unclassified. ABC cases exhibited a higher lymphoma-related mortality (LRM). Next-generation sequencing analysis showed mutations in 158/184 evaluated genes. The most frequently mutated genes were KMT2D (42.6%), SETD1B (33.3%), RERE (29.4%), FAS and PIM1 (27.8%) and TBL1XR1 (25.9%). A mutation in the NOTCH pathway was detected in 25.9% of cases and was associated with worst LRM. Cluster analysis by LymphGen classified 29/54 cases within definite groups, including BN2 in 14 (48.2%), ST2 in seven (24.2%) and MCD and EZB in four each (13.8%). Overall, these results indicate a preferential marginal zone origin for a consistent subgroup of HCV-associated DLBCL cases and suggest potential implications for molecularly targeted therapies.
(© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
References: Cacoub P, Saadoun D. Extrahepatic manifestations of chronic HCV infection. N Engl J Med. 2021;384(11):1038–1052.
Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, et al. Characteristics and outcome of diffuse large B‐cell lymphoma in hepatitis C virus‐positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol. 2006;24(6):953–960.
Visco C, Arcaini L, Brusamolino E, Burcheri S, Ambrosetti A, Merli M, et al. Distinctive natural history in hepatitis C virus positive diffuse large B‐cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol off J Eur Soc Med Oncol. 2006;17(9):1434–1440.
Merli M, Visco C, Spina M, Luminari S, Ferretti VV, Gotti M, et al. Outcome prediction of diffuse large B‐cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica. 2014;99(3):489–496.
Besson C, Noel N, Lancar R, Prevot S, Algarte‐Genin M, Rosenthal E, et al. Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. AIDS England. 2020;34(4):599–608.
Arcaini L, Rossi D, Lucioni M, Nicola M, Bruscaggin A, Fiaccadori V, et al. The notch pathway is recurrently mutated in diffuse large B‐cell lymphoma associated with hepatitis c virus infection. Haematologica. 2015;100(2):246–252.
Pecoraro V, Banzi R, Cariani E, Chester J, Villa E, D'Amico R, et al. New direct‐acting antivirals for the treatment of patients with hepatitis C virus infection: a systematic review of randomized controlled trials. J Clin Exp Hepatol. 2019;9(4):522–538.
Arcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M, et al. Interferon‐free antiviral treatment in B‐cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016;128(21):2527–2532.
Frigeni M, Besson C, Visco C, Fontaine H, Goldaniga M, Visentini M, et al. Interferon‐free compared to interferon‐based antiviral regimens as first‐line therapy for B‐cell lymphoproliferative disorders associated with hepatitis C virus infection. Leukemia. 2020;34(5):1462–1466.
Peveling‐Oberhag J, Arcaini L, Bankov K, Zeuzem S, Herrmann E. The anti‐lymphoma activity of antiviral therapy in HCV‐associated B‐cell non‐Hodgkin lymphomas: a meta‐analysis. J Viral Hepat England. 2016;23(7):536–544.
Merli M, Rattotti S, Spina M, Re F, Motta M, Piazza F, et al. Direct‐acting antivirals as primary treatment for hepatitis C virus–associated indolent non‐Hodgkin lymphomas: the BArT study of the Fondazione Italiana Linfomi. J Clin Oncol. 2022;40(35):4060–4070.
Merli M, Frigeni M, Alric L, Visco C, Besson C, Mannelli L, et al. Direct‐acting antivirals in hepatitis C virus‐associated diffuse large B‐cell lymphomas. Oncologist. 2019;24(8):e720–e729.
Merli M, Defrancesco I, Visco C, Besson C, Di Rocco A, Arcari A, et al. Direct‐acting antivirals in relapsed or refractory hepatitis C virus‐associated diffuse large B‐cell lymphoma. Leuk Lymphoma. 2020;61(9):2122–2128.
Arcari A, Tabanelli V, Merli F, Marcheselli L, Merli M, Balzarotti M, et al. Biological features and outcome of diffuse large B‐cell lymphoma associated with hepatitis C virus in elderly patients: results of the prospective “elderly project” by the Fondazione Italiana Linfomi. Br J Haematol England. 2023;201(4):653–662.
Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B‐cell lymphoma. N Engl J Med. 2018;378(15):1396–1407.
Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690.
Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551–568. e14.
Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological malignancy research network report. Blood. 2020;135(20):1759–1771.
Visco C, Wang J, Tisi MC, Deng L, D'Amore ESG, Tzankov A, et al. Hepatitis C virus positive diffuse large B‐cell lymphomas have distinct molecular features and lack BCL2 translocations. Br J Cancer. 2017;117(11):1685–1688.
Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012;209(9):1537–1551.
Bonfiglio F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022;139(5):732–747.
Armand M, Degaud M, Tesson B, Laurent C, Vavasseur M, Parisot M, et al. Exploring the genetic landscape of HCV‐related B‐cell lymphomas using whole exome sequencing. Leukemia. 2023;37(6):1388–1391.
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, de Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non‐Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3067.
International Non‐Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non‐Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987–994.
Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised international prognostic index (R‐IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B‐cell lymphoma treated with R‐CHOP. Blood. 2007;109(5):1857–1861.
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B‐cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
Scott DW, Wright GW, Williams PM, Lih C‐JJ, Walsh W, Jaffe ES, et al. Determining cell‐of‐origin subtypes of diffuse large B‐cell lymphoma using gene expression in formalin‐fixed paraffin‐embedded tissue. Blood. 2014;123(8):1214–1217.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
Rossi D, Bertoni F, Zucca E. Marginal‐zone lymphomas. N Engl J Med. 2022;386(6):568–581.
Merli M, Arcaini L. Management of marginal zone lymphomas. Hematology. 2022;2022(1):676–687.
Merli M, Passamonti F, Arcaini L. Deciphering molecular complexity of HCV‐associated lymphoproliferation. Br J Haematol England. 2023;203(2):154–157.
Canioni D, Michot J‐M, Rabiega P, Molina TJ, Charlotte F, Lazure T, et al. In situ hepatitis C NS3 protein detection is associated with high grade features in hepatitis C‐associated B‐cell non‐Hodgkin lymphomas. PloS One. 2016;11(6):e0156384.
Flossbach L, Antoneag E, Buck M, Siebert R, Mattfeldt T, Möller P, et al. BCL6 gene rearrangement and protein expression are associated with large cell presentation of extranodal marginal zone B‐cell lymphoma of mucosa‐associated lymphoid tissue. Int J Cancer. 2011;129(1):70–77.
Rosenwald A, Bens S, Advani R, Barrans S, Copie‐Bergman C, Elsensohn M‐H, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B‐cell lymphoma: a study by the Lunenburg lymphoma biomarker consortium. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(35):3359–3368.
Xu‐Monette ZY, Dabaja BS, Wang X, Tu M, Manyam GC, Tzankov A, et al. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B‐cell lymphoma patients treated with rituximab‐CHOP. Mod Pathol. 2015;28(12):1555–1573.
Defrancesco I, Visentini M, Zibellini S, Minafò YA, Rattotti S, Ferretti VV, et al. Mutational and immunogenetic landscape of HCV‐associated B‐cell lymphoproliferative disorders. Am J Hematol. 2021;96:E210–E214.
Parry M, Rose‐Zerilli MJJ, Ljungström V, Gibson J, Wang J, Walewska R, et al. Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing. Clin Cancer Res. 2015;21(18):4174–4183.
Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non‐germinal center B‐cell diffuse large B‐cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(15):1285–1295.
Zhang M‐C, Tian S, Fu D, Wang L, Cheng S, Yi H‐M, et al. Genetic subtype‐guided immunochemotherapy in diffuse large B cell lymphoma: the randomized GUIDANCE‐01 trial. Cancer Cell. 2023;41(10):1705–1716.e5.
Wilson WH, Wright GW, Huang DW, Hodkinson B, Balasubramanian S, Fan Y, et al. Effect of ibrutinib with R‐CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39(12):1643–1653.e3.
Noy A, de Vos S, Coleman M, Martin P, Flowers CR, Thieblemont C, et al. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long‐term follow‐up and biomarker analysis. Blood Adv. 2020;4(22):5773–5784.
Opat S, Tedeschi A, Linton K, McKay P, Hu B, Chan H, et al. The MAGNOLIA trial: Zanubrutinib, a next‐generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma. Clin Cancer Res. 2021;27(23):6323–6332.
Matasar MJ, Luminari S, Barr PM, Barta SK, Danilov AV, Hill BT, et al. Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs. Oncologist. 2019;24(11):e1236–e1250.
Merli M, Frigeni M, Gotti M, Grossi P, Bruno R, Passamonti F, et al. Direct‐acting antivirals during or after immunochemotherapy in hepatitis C virus‐positive diffuse large B‐cell lymphomas. Hepatology. 2017;66(4):1341–1343.
معلومات مُعتمدة: Ricerca Corrente Fondazione IRCCS Policlinico San Matteo" (P.I. Luca Arcaini); ID.20767project AIRC (under IG 2017) P.I. Luca Arcaini); Italian Ministry of Education, University and Research (MIUR) to the Departments of Molecular Medicine (DMM); Fondazione Matarelli, Milano (Italy)
فهرسة مساهمة: Keywords: NGS; Nanostring; diffuse large B‐cell lymphoma; hepatitis C virus
تواريخ الأحداث: Date Created: 20240305 Date Completed: 20240614 Latest Revision: 20240614
رمز التحديث: 20240614
DOI: 10.1111/bjh.19378
PMID: 38442902
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-2141
DOI:10.1111/bjh.19378